US Patent RE41393 Treatment of refractory tumors using epothilone derivatives

Patent RE41393 was granted and assigned to Bristol-Myers Squibb on June, 2010 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Current Assignee

Bristol-Myers Squibb

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

RE41393

Patent Inventor Names

Francis Y.F. Lee0

Date of Patent

June 22, 2010

Patent Application Number

11346579

Date Filed

February 2, 2006

Patent Primary Examiner

‌

James D. Anderson

Patent abstract

Methods of treating tumors in a mammal, especially a human that has demonstrated resistance to other chemotherapeutic agents, is disclosed. Specifically, methods of the present invention are effective in tumors that have initially been unresponsive to taxane therapy, or have developed resistance during the course of treatment. The methods of the present invention comprise administering epothilone derivatives selected from those represented by the formula:The subject epothilone derivatives are advantageous in addition to their enhanced potency and effectiveness against tumors that have demonstrated resistance to therapy with taxane oncology agents in that they are efficacious upon oral administration.